A Roadmap for Results - Understanding the ECHO Trial Findings

Read more
ECHO presentation

Results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were released at a session at the 9th South African AIDS Conference (SA AIDS 2019) in Durban, South Africa, on Thursday, June 13th. The session, which included presentations on the primary analysis, was recorded and can be viewed on YouTube here.

June 13, 2019
Year of publication
2019
Resource types
Conference materials, Video and audio clips
Topics
Gender, Women, HIV programming and implementation science, Data use, Scale-up and replication, Prevention, Microbicides, Prevention programming, Reproductive Health and Family Planning, HIV/Family planning integration
Countries
South Africa
Tags
Echo trial, ECHO study, contraception, family planning, dual contraception, DMPA, depo-medroxyprogesterone acetate, Depo Provera, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study, SA AIDS 2019, 9th South African AIDS Conference

Similar Resources

Young Women’s Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa

End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy.

ECHO Study Factsheet
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label randomised clinical trial comparing three highly effective, reversible methods of contraception — a progestogen-only injectable called depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant and the non…
Recording and Q&A session: Improving early infant diagnosis webinar

An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.

Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology

Multipurpose prevention technologies (MPTs) are preferably single dosage forms designed to simultaneously address multiple sexual and reproductive health needs, such as unintended pregnancy, HIV infection and other sexually transmitted infections (STIs).

DREAMS Country Fact Sheets: South Africa

DREAMS is an ambitious $385 million partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women.

The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa

A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection.

What Works in Treatment for Pregnant Women Living with HIV? The Latest Evidence is Now Available at WhatWorksforWomen.org

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

DREAMS Country Fact Sheets: Kenya

DREAMS is an ambitious $385 million partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women.

DREAMS Country Fact Sheets: Lesotho

DREAMS is an ambitious $385 million partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women.

DREAMS Country Fact Sheets: Malawi

DREAMS is an ambitious $385 million partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women.